Intel said on Wednesday that Microsoft plans to use its services to manufacture a custom computing chip and that the company expects to beat an internal deadline of 2025 to overtake its biggest rival, Taiwan Semiconductor Manufacturing Co, in advanced chip manufacturing.
Neutron stars in the universe, ultracold atomic gases in the laboratory, and the quark–gluon plasma created in collisions of atomic nuclei at the Large Hadron Collider (LHC): they may seem totally unrelated but, surprisingly enough, they have something in common.
They are all a fluid-like state of matter made up of strongly interacting particles. Insights into the properties and behavior of any of these almost-perfect liquids may be key to understanding nature across scales that are orders of magnitude apart.
In a new paper, the CMS collaboration reports the most precise measurement to date of the speed at which sound travels in the quark–gluon plasma, offering new insights into this extremely hot state of matter.
Researchers are working on ways to improve the effectiveness of currently approved bile duct cancer, also called cholangiocarcinoma, treatments and finding early success in the development of more targeted therapies. Read more on the AACR Blog:
To overcome this issue, researchers are exploring next-generation FGFR inhibitors. During the 2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in January 2024, phase II clinical trial results were announced for tinengotinib, a FGFR1-3 inhibitor that binds to FGFR in a way that blocks FGFR2 fusion and rearrangement, preventing the mutations that cause resistance to treatment. Of the patients in the trial whose tumors had developed resistance to a previous FGFR inhibitor, 37.5% demonstrated a partial response with tumor reductions ranging from 40.7% to 54.6%. A phase III trial for the drug candidate kicked off in December 2023.
Other next-generation FGFR inhibitors are in various stages of development, including RLY-4008 (phase I/II trial), erdafitinib (phase IIa), KIN-3248 (phase I/Ib), derazantinib (phase II), tasurgratinib (phase II), and HMPL-453 (phase II).
Continue reading “Finding the Right Targets to Treat Biliary Tract Cancers” »
Contrary to popular perception, traumatic brain injury (TBI) is not the reserve of car accidents and punishing contact sports; it’s surprisingly common. Up to 50 million new cases of traumatic brain injury are registered each year worldwide. Notably, 80% of TBI occurs in low-to middle-income countries, and it is also the leading cause of death and disability in young adults. Overall, the global economic burden of TBI is estimated at 400 billion USD.
Minimising the devastating effects of TBI doesn’t rely solely on reducing the risk of an injury; it’s also essential to improve treatment after one has happened. For that, physiological real-time monitoring of vital signals is critical. One inventor has made it his mission to create devices that can do this accurately, easily, anywhere, and what’s more, they are also non-invasive.
Professor Arminas Ragauskas is a founder and director of the Health Telematics Science Institute at Kaunas University of Technology in Lithuania, which develops innovative industrial and physiological measurement and process monitoring technologies. He is particularly known for his work on non-invasive intracranial pressure and cerebral blood flow autoregulation measurement devices. He was also the national coordinator of the CENTER-TBI project, funded by the European Commission and the EU industry, with a budget of 40 million EUR, and focused European efforts to advance the care of patients with traumatic brain injury.
The universe’s brightest object is a quasar in a distant galaxy that’s powered by the fastest-growing black hole ever recorded, according to a new study.
Microsoft presents LongRoPE
Extending LLM context window beyond 2 million tokens.
Join the discussion on this paper page.
While current diagnostic definitions of attention-deficit hyperactivity disorder (ADHD) are relatively new, the general condition has been identified by clinicians under a variety of names for centuries. Recent genetic studies have revealed the condition to be highly heritable, meaning the majority of those with the condition have genetically inherited it from their parents.
Depending on diagnostic criteria, anywhere from two to 16% of children can be classified as having ADHD. In fact, increasing rates of diagnosis over recent years have led to some clinicians arguing the condition is overdiagnosed.
What is relatively clear, however, is that the behavioural characteristics that underpin ADHD have been genetically present in human populations for potentially quite a long time. And that has led some researchers to wonder what the condition’s evolutionary benefits could be.
Princeton researchers report that a new AI model has solved one of the major roadblocks to generating fusion energy.
